Network modeling analysis using Transcriptional Regulatory Associations in Pathways (TRAP) suggested CDK4 as an efficient target to be associated with MEK inhibitors in the treatment of melanoma harboring NRAS mutations which remains without effective therapy [111]. The gene discussed is MAP2K7; the disease is melanoma.